Kiora Pharmaceuticals (KPRX) Net Margin (2016 - 2024)

Kiora Pharmaceuticals' (KPRX) quarterly Net Margin came in at 11108.23% in Q2 2024, down 13311.1% quarter-over-quarter from 84.08% in Q1 2024.

Analysis

Kiora Pharmaceuticals (KPRX) Net Margin (2016 - 2024) Analysis & Trends

Kiora Pharmaceuticals (KPRX) has reported Net Margin for 6 consecutive years, with 11108.23% the latest figure, recorded in Q2 2024.

For the quarter ending Q2 2024, Net Margin changed N/A year-over-year to 11108.23%; the trailing twelve-month figure through Mar 2025 stood at 60257.27% (down 6022203.0% YoY), and the FY2024 full-year result was 22.44%, changed N/A from the prior year.
Net Margin declined to 11108.23% in Q2 2024 per KPRX's latest filing, from 84.08% in the prior quarter.
Across five years, Net Margin topped out at 84.08% in Q1 2024 and bottomed at 11108.23% in Q2 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Johnson & Johnson	641.31 Bn	620.55 Bn	17.26 Bn	21.86%
2	AbbVie	445.49 Bn	438.92 Bn	12.70 Bn	21.28%
3	Merck	357.41 Bn	350.27 Bn	12.21 Bn	-8.05%
4	Novartis Ag	267.66 Bn	259.97 Bn	11.24 Bn	22.65%
5	Pfizer	156.81 Bn	145.11 Bn	10.94 Bn	-1.58%
6	Sanofi	52.17 Bn	44.78 Bn	10.79 Bn	2.96%
7	Revolution Medicines	42.94 Bn	42.94 Bn	-	-
8	Incyte	24.61 Bn	20.07 Bn	1.57 Bn	34.98%
9	United Therapeutics	21.31 Bn	18.64 Bn	683.80 Mn	42.51%
10	Kiora Pharmaceuticals	15.44 Mn	15.44 Mn	-	-

Historic Data

Download Data